Search Within

Heiko Schoder

  1. "GSK Faculty"
Formats
  1. Journal Article (94)
  2. Meeting Abstract (56)
  3. Book Section (4)
  4. Review (3)
  5. Editorial (2)
  6. Research Letter (2)
Groups
  1. GSK Faculty (161)
  2. Molecular Imaging and Therapy Service (161)
  3. Radiology, Department of (161)
  4. Molecular Pharmacology and Chemistry Program Faculty (117)
  5. Sloan Kettering Institute Faculty (117)
  6. Department of Medicine (90)

More Groups

People
  1. Steven Larson (93)
  2. John Humm (41)
  3. Mithat Gonen (28)
  4. Howard Scher (23)
  5. Henry Yeung (22)
  6. Josef Fox (22)

More People

Years
  1. 2025 (5)
  2. 2024 (13)
  3. 2023 (15)
  4. 2022 (3)
  5. 2021 (10)
  6. 2020 (9)

More Years

Publications
  1. Journal of Nuclear Medicine (40)
  2. Journal of Clinical Oncology (23)
  3. Blood (12)
  4. European Journal of Nuclear Medicine and Molecular Imaging (12)
  5. International Journal of Radiation Oncology, Biology, Physics (9)
  6. Medical Physics (5)

More Publications

Publishers
  1. Society of Nuclear Medicine (40)
  2. American Society of Clinical Oncology (23)
  3. Springer (21)
  4. Elsevier Inc. (16)
  5. American Society of Hematology (13)
  6. Lippincott Williams & Wilkins (8)

More Publishers

Results (161)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • PET‐adapted therapy with nivolumab plus adriamycin, vinblastine, and dacarbazine for newly diagnosed stage III or IV Hodgkin Lymphoma
    Meeting Abstract

    Moskowitz, A.; Savage, K.; Feldman, T.; Ganesan, N.; Hancock, H.; Davey, T.; Perez, L.; Santarosa, A.; Subzwari, S.; Capadona, C.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Phase 2 trial of nivolumab plus adriamycin, vinblastine, dacarbazine (N‐AVD) as frontline therapy in older adults with Hodgkin lymphoma
    Meeting Abstract

    Torka, P.; Feldman, T.; Savage, K.; Ganesan, N.; Hancock, H.; Davey, T.; Perez, L.; Santarosa, A.; Subzwari, S.; Capadona, C.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Polyethylene glycol 3350 (PEG 3350) as a practical vehicle for rapid reconstitution of PARPi-FL formulations for clinical use
    Journal Article

    de Souza França, P. D.; Viray, T.; Roberts, S.; Michel, A.; Abrahão, M.; Patel, S. G.; Ganly, I.; Schöder, H.; Brand, C.; Reiner, T.; more...
    Molecular Imaging and Biology (2023)

    Fulltext@MSK | Save
  • Foreword
    Book Section

    Hricak, H.; Schöder, H.
    In Veit-Haibach, P.; Herrmann, K. (Eds.) Artificial Intelligence/Machine Learning in Nuclear Medicine and Hybrid Imaging (2022)

    Fulltext@MSK | Save
  • Immune signature of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma
    Meeting Abstract

    Wills, B.; Ganesan, N.; Shah, G. L.; Wong, P.; Argyropoulos, K. V.; Sen, F.; Dogan, A.; Straus, D. J.; Noy, A.; Kumar, A.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Radiotheranostics in oncology: Current challenges and emerging opportunities
    Review

    Bodei, L.; Herrmann, K.; Schöder, H.; Scott, A. M.; Lewis, J. S.
    Nature Reviews Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Interim efficacy analysis of a phase II study demonstrates promising activity of the combination of pembrolizumab (PEM) and entinostat (ENT) in relapsed and refractory (R/R) Hodgkin lymphoma (HL)
    Meeting Abstract

    Sermer, D. J.; Vardhana, S.; Biggar, E.; Moskowitz, A. J.; Joffe, E.; Khan, N.; Straus, D. J.; Kumar, A.; Zelenetz, A. D.; Horwitz, S. M.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Precision radiotherapy: Reduction in radiation for oropharyngeal cancer in the 30 ROC trial
    Journal Article

    Riaz, N.; Sherman, E.; Pei, X.; Schöder, H.; Grkovski, M.; Paudyal, R.; Katabi, N.; Selenica, P.; Yamaguchi, T. N.; Ma, D.; more...
    JNCI: Journal of the National Cancer Institute (2021)

    Fulltext@MSK | Save
  • A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomas
    Journal Article

    Moskowitz, A. J.; Ghione, P.; Jacobsen, E.; Ruan, J.; Schatz, J. H.; Noor, S.; Myskowski, P.; Vardhana, S.; Ganesan, N.; Hancock, H.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Imaging HER2-positive metastatic esophagogastric cancer with (89)Zr-trastuzumab PET and (18)F-FDG PET
    Meeting Abstract

    Lumish, M. A.; Maron, S. B.; Paroder, V.; Philemond, S.; O'Donoghue, J. A.; Schoder, H.; Lewis, J. S.; Janjigian, Y. Y.; Pandit-Taskar, N.
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save